Soluble CD40 ligand in prediction of acute severe pancreatitis

FROSSARD, Jean-Louis, et al.

Abstract
To assess the early predictability of the soluble CD40L (sCD40L) in pancreatitis severity.

Reference
FROSSARD, Jean-Louis, et al. Soluble CD40 ligand in prediction of acute severe pancreatitis. *World Journal of Gastroenterology*, 2006, vol. 12, no. 10, p. 1613-6

PMID: 16570356
Soluble CD40 ligand in prediction of acute severe pancreatitis

Jean Louis Frossard, Philippe Morel, Brenda Kwak, Catherine Pastor, Thierry Berney, Léo Buhler, Alain Von Laufen, Sandrine Demulder, François Mach

AIM: To assess the early predictability of the soluble CD40L (sCD40L) in pancreatitis severity.

METHODS: Between February 2000 and February 2003, 279 consecutive patients with acute pancreatitis were prospectively enrolled in our study. In this report, 40 patients with mild and 40 patients with severe pancreatitis were randomly studied. sCD40L concentrations were measured 48 hours after admission.

RESULTS: sCD40L levels were significantly higher 48 hours after admission in severe pancreatitis than in mild pancreatitis. Using a cutoff of 1000 pg/L, the sensitivity and specificity of sCD40L to detect a severe course of the disease were 78% and 62% respectively compared to 72% and 81% for CRP. Logistic regression analysis found that CRP was the only statistically significant marker able to detect a severe course of the disease.

CONCLUSION: These findings indicate that CRP remains a valuable marker to determine the severity and prognosis of acute pancreatitis whereas sCD40L levels should be assessed in further studies.

http://www.wjgnet.com/1007-9327/12/1613.asp

INTRODUCTION

Acute pancreatitis (AP) is a disease of variable severity. While approximately 80% of patients experience mild attacks, the remaining 20% still suffer from severe disease, with a mortality rate as high as 30%. Since treatment of patients with severe disease is currently mostly supportive and directs at either prevention or control of the local and systemic complications, the early prediction of the severity of AP is the main goal of clinicians in charge of such patients. Multifactorial scales including Ranson and APACHE II scoring systems have been used in acute pancreatitis since the 1980s. Ranson scale has been used in the 1980s in virtually all studies dealing with acute pancreatitis. The list of 11 numerical parameters proposed by Ranson has no been fully discussed because only 5 criteria are obtained at admission and the remaining 6 during the subsequent 48 hour period, delay the performance of an early prediction. Moreover, the complexity of these scales and perhaps the fact that CT scanners are not available in every hospital account for the increasing interest in serum markers.

The pathophysiology of acute pancreatitis includes the activation and release of pancreatic enzymes in the interstitium, pancreatic autodigestion, and a multiple organ dysfunction following the release of these enzymes into the systemic circulation. There is evidence that synthesis and release of pro-inflammatory cytokines and chemokines are also responsible for local and distant injuries. If the concentration of these biological factors is correlated to the severity of the disease and if they are detected before the occurrence of multiple organ dysfunction, these factors might be important for the rapid scoring of the disease severity in the acute phase.

CD40, a proteic member of the tumour necrosis factor receptor family, is expressed on the membrane of a variety of cells, including B lymphocytes, monocytes, biliary and acinar cells as recently shown by our group. CD40 binds to its ligand CD40L, a membrane glycoprotein, to mediate major immunoregulatory signals involved in auto-immune disease, graft rejection, inflammatory bowel disease, development of atherosclerosis and acute experimental pancreatitis. We postulated that CD40-CD40L interactions might also play a role in the pathogenesis of human pancreatitis and that the soluble form of CD40L
(sCD40L) levels might be correlated to the severity of the disease. The purpose of this study was to assess the early predictability of sCD40L in pancreatitis severity.

**MATERIALS AND METHODS**

The study protocol was approved by the local Ethics Committee. Upon admission, all patients with acute pancreatitis meeting the criteria of inclusion were identified and proposed to be included in the study. Before inclusion, each patient gave an informed consent. Between February 2000 and February 2003, 279 consecutive patients with acute pancreatitis were prospectively enrolled in our study. We assessed the role of sCD40L in the prediction of the severity of pancreatitis in this preliminary study. Consequently, 40 patients with mild and 40 patients with severe pancreatitis were randomly evaluated in the current study (Table 1). Ten healthy controls from our own divisions were also used for comparison. Inclusion criteria were typical abdominal pain associated with serum amylase twice the upper limit value (range: 26-128 U/L). The diagnosis was subsequently confirmed by CT scan with a Picker 1200 or a PQ-2000 instrument. Intravenous contrast material (Omnipaque 350, Shering, Germany) was injected and multiple scans were obtained from the pancreas to the pelvis as previously described[12]. Pancreatic necrosis was considered significant if there was > 30% necrosis of the gland. Pancreatitis severity was defined according to the Atlanta classification and included organ failure (e.g., shock, pulmonary insufficiency, renal failure), the presence of local complications (pancreatic necrosis, pseudocysts, abscess), or both[13]. Blood samples drawn 48 hours after admission were used to measure CRP and sCD40L using commercially available kits (Behring, Marburg, Germany and Bender MedSystems Vienna, Austria).

**Statistical analysis**

Serum markers were compared during severe and mild attacks by univariate analysis (Student’ t-test, Mann-Whitney). SCD40L, CRP and Ranson scores were evaluated by receiver operating characteristics (ROC) curves for selected sCD40L and historically determined (CRP and Ranson) cutoff levels[3,4,5]. The cutoff for CRP (150 mg/L) and Ranson (severe > 3) was chosen according to the literature[4,5]. The cutoff for sCD40L was chosen according to its ROC curve. A logistic regression analysis for the binary outcome of mild or severe pancreatitis was performed. P<0.05 was considered statistically significant. Statistics calculations were done using SPSS Software package (Chicago, USA).

**RESULTS**

The delay between the onset of abdominal pain and admission ranged from 7 hours to 2 d (Table 1). The aetiology of acute pancreatitis was biliary in 38 patients (48%), alcoholism in 30 (38%), drug-induced pancreatitis in 2 (3 %), hypertriglyceridemia in 1 (2 %) and idiopathic in the remaining 9 patients (11%) (Table1).

CT scan was obtained within 36 hours after admission in each patient and showed a normal pancreas in 5 patients, edema in 47 patients and necrosis in 28 patients (Table 1). Acute fluid collections were found in 35 patients (43 %) (Table1). The Ranson score established at 48 hours was ≥ 3 in 27 patients (33 %), 19 of whom had severe pancreatitis and 8 mild pancreatitis. Sensitivity, specificity, positive predictive value, and negative predictive value of Ranson

---

**Table 1 Characteristics of the population**

|                     | Control group | Mild pancreatitis | Severe pancreatitis | P value |
|---------------------|---------------|-------------------|---------------------|---------|
| n                   | 10            | 40                | 40                  |         |
| Male/female         | 5/5           | 27/13             | 31/9                | 0.33    |
| Age (year)          | 33.5 (31.2-35.3) | 52.5 (51.5-62.7) | 58.5 (56.1-66.6)    | 0.21    |
| Serum amylase (U/L) | 98 (75-128)   | 356 (352-682)     | 474 (451-1238)      | 0.34    |
| Delay after onset (hours) | -     | 20.1 (18.2-22.4) | 22.2 (19.5-23.2)    | 0.58    |
| Cause of AP         |               |                   |                     |
| - biliary           | -             | 17                | 21                  | 0.5     |
| - alcohol           | -             | 14                | 16                  | 0.6     |
| - other             | -             | 2                 | 1                   | 0.6     |
| - idiopathic        | -             | 7                 | 2                   | 0.15    |
| - Ranson > 3        | -             | 8                 | 19                  | 0.017   |
| Ranson value        | -             | 2 (1.5-2.1)       | 2 (1.9-2.6)         |         |
| sCD40L (pg/L)       | 22 (16.3-28.1)| 795 (692-1301)    | 1215 (1186-1753)    |         |
| CRP levels (mg/L)   | 12.2 (9.3-15.5)| 42.5 (50.1-101.7)| 225.5 (199.8-319.4) |         |
| CT scan             |               |                   |                     |
| - normal            | -             | 5                 | 0                   | 0.021   |
| - edematous         | -             | 28                | 19                  | 0.04    |
| - necrosis          | -             | 19                | 9                   | 0.02    |
| - collection        | -             | 8                 | 27                  | 0.0001  |
| Death               | -             | 0                 | 3                   | 0.07    |

Values are expressed as median values (CI 95%).
and sCD40L (Figure 2). The forward stepwise analysis better delineate the performance of Ranson score, CRP and sCD40L results were evaluated by logistic regression analysis found that CRP at d 2 was the only statistically significant parameter to predict a severe disease ($P < 0.001$).

### DISCUSSION

Predicting the course of acute pancreatitis remains a challenge for the physician.[4] Moreover, the 48-hour delay necessary to collect the standard scores and the complexity of multifactorial scales have prompted many physicians to investigate new markers.[5] CRP is an acute phase protein produced by the liver during inflammatory conditions that was first described in 1930[1]. In the mid-1980s, several studies showed that CRP could be considered as a valuable prognostic factor for severe pancreatitis.[5,6] Indeed, a better understanding of the pathophysiology of acute pancreatitis may contribute to a better selection of a specific prognostic marker. To this end, CD40-CD40L interaction, a major pro-inflammatory system widely distributed on a variety of leukocytes, has been recently studied in experimental rodent pancreatitis.[7] The expression of CD40 and its ligand were detected on pancreatic acinar cell surface, and peripheral T lymphocytes showed a progressive increase in the expression of CD40L during the course of experimental pancreatitis. Taken together, we thought that these findings might be applied to human pancreatitis. In the current report where 40 patients with mild and 40 patients with severe pancreatitis were randomly evaluated, we showed for the first time that the levels of the soluble form of CD40L (sCD40L) were higher in severe than in mild pancreatitis 48 hours after admission. The usefulness of this potential new marker has been compared to CRP, the most widely accepted serum marker that is used on a daily routine in almost all hospitals. Indeed, a second time that the levels of the soluble marker characterized by a better negative predictive allows to exclude a severe disease was superior than that by CRP. A marker characterized by a better negative predictive allows cost savings since it can avoid useless observation time in emergency room or intensive care unit.[8,9] However, logistic regression analysis found that CRP was the only statistically significant marker able to identify a patient who developed a severe course of the disease. One explanation for this result is that our study was limited by the

| Table 2 Performances of sCD40L, CRP and RANSON score |
|-----------------------------------------------|
| Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) |
|----------------|----------------|-----------------------------|-----------------------------|
| sCD40L (cutoff 1000 pg/L) | 77 | 62 | 63 | 74 |
| CRP (150 mg/L) | 72 | 81 | 80 | 74 |
| RANSON Score (>3) | 48 | 80 | 70 | 60 |

**FIGURE 1** Soluble CD40L concentrations in healthy controls, severe and mild pancreatitis patients. Horizontal bars delineate the mean value.

**FIGURE 2** sCD40L (400, 800, 1000, 1200, 1400 and 2000 pg/L), CRP (50, 150 and 200 mg/L) and Ranson (Ranson score of 2, 3 and 4) ROC curves with selected or historically determined cutoffs in patients with mild and severe pancreatitis.
small number of patients evaluated. Consequently, correlation between the levels of sCD40L and the occurrence of complications or death for example could not be studied.

Of note, Ranson score appeared insufficiently predictive of severe attacks, a feature already reported in several previous prospective studies\textsuperscript{14,17,18}. To predict the severity of pancreatic disease itself, before the occurrence of multiple organ dysfunction, numerous other factors besides CRP have been evaluated so far with various performances. These factors are either enzymes released from the pancreas such as trypsinogen activation peptide\textsuperscript{16} or mediators induced by inflammation in the pancreas itself or in remote organs such as procalcitonin\textsuperscript{19}, adhesion molecules\textsuperscript{20} or cytokines\textsuperscript{21}. For most of them, the higher the blood concentrations of these enzymes or mediators are, the more severe the disease is. Soluble CD40L could be one of the next markers of pancreatitis severity but further larger studies are needed to validate its clinical use in the early assessment of pancreatitis severity.

REFERENCES

1. Tikhonova EP. Elimination of the instability of blood glucose level as a measure of increasing the effectiveness of insulin therapy in insulin-dependent diabetes mellitus. Ter Arkh 1989; 61: 81-84
2. Williamson RC. Early assessment of severity in acute pancreatitis. Gut 1984; 25: 1331-1339
3. Ranson JH, Pasternack BS. Statistical methods for quantifying the severity of clinical acute pancreatitis. J Surg Res 1977; 22: 79-91
4. Wilson C, Heath DJ, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. Br J Surg 1990; 77: 1260-1264
5. Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans. Am J Respir Crit Care Med 2001; 164: 162-170
6. Frossard JL. Trypsin activation peptide (TAP) in acute pancreatitis: from pathophysiology to clinical usefulness. JOP 2001; 2: 69-77
7. Frossard JL, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. Cd40 ligand-deficient mice are protected against cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 2001; 121: 184-194
8. Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, Steer ML. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 1999; 116: 694-701
9. Pastor CM, Matthy MA, Frossard JL. Pancreatitis-associated acute lung injury: new insights. Chest 2003; 124: 2341-2351
10. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998; 137 Suppl: S89-S95
11. Daoussis D, Andonopoulos AP, Liossis SS. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol 2004; 11: 635-641
12. Robert JH, Frossard JL, Mermillod B, Soravia C, Mensi N, Roth M, Rohner A, Hadengue A, Morel P. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glasgow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers. World J Surg 2002; 26: 612-619
13. Bradley EL. 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993; 128: 586-590
14. Puolakkainen P, Valtonen V, Paananen A, Schroder T. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 1987; 28: 764-771
15. Herouy Y, Hellstern MO, Vanscheidt W, Schoepf E, Norgauer J. Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers. Lancet 2000; 355: 1970-1971
16. Frossard JL. Trypsinogen activation peptide in acute pancreatitis. Lancet 2000; 356: 766-767
17. Frossard JL, Robert J, Soravia C, Mensi N, Magnin A, Hadengue A, Rohner A, Morel P. Early prediction in acute pancreatitis: the contribution of amylase and lipase levels in peritoneal fluid. JOP 2000; 1: 36-45
18. Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gynec Obstet 1976; 143: 209-219
19. Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41: 832-840
20. Kaufmann P, Tilz GP, Smolle KH, Demel U, Krejs GJ. Increased plasma concentrations of circulating intercellular adhesion molecule-1 (ICAM-1) in patients with necrotizing pancreatitis. Immunobiology 1996; 195: 209-219
21. Frossard JL. Pathophysiology of acute pancreatitis: a multistep disease. Acta Gastroenterol Belg 2003; 66: 166-173

S- Editor Guo SY L- Editor Zhang JZ E- Editor Liu WF